421 related articles for article (PubMed ID: 30149766)
1. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract][Full Text] [Related]
2. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
5. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
6. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of patients with metastatic melanoma.
Yu Z; Si L
Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
9. [Advances in immunotherapy for metastatic melanoma].
Oláh J
Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
[TBL] [Abstract][Full Text] [Related]
10. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
[TBL] [Abstract][Full Text] [Related]
11. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
12. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
13. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of melanomas].
Zimmer L; Vaubel J; Schadendorf D
Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
[TBL] [Abstract][Full Text] [Related]
15. [Advances in Immunotherapy of Malignant Melanoma].
Krajsová I
Klin Onkol; 2017; 30(Supplementum3):40-44. PubMed ID: 29239191
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.
Bhandaru M; Rotte A
Methods Mol Biol; 2019; 1904():83-108. PubMed ID: 30539467
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Melanoma.
Albittar AA; Alhalabi O; Glitza Oliva IC
Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of melanoma.
Kee D; McArthur G
Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
[TBL] [Abstract][Full Text] [Related]
20. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
